05:27 PM EDT, 09/19/2024 (MT Newswires) -- AngioDynamics ( ANGO ) said Thursday it started a trial of AlphaVac Multipurpose Mechanical Aspiration F18 system for the treatment of acute pulmonary embolism.

The multicenter, multinational, single-arm study will evaluate the efficacy, safety and long-term functional outcomes of percutaneous mechanical aspiration thrombectomy using AlphaVac system. The trial will support the adoption of the device in the European market, according to the company.

The primary endpoint of the trial is a reduction in right ventricular to left ventricular ratio from baseline 48 hours after the procedure.

Price: 7.80, Change: +0.10, Percent Change: +1.30